Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
Clinical trial NCT02353715 · COMPLETED
Trial details
- NCT number
- NCT02353715
- Sponsor
- Duke University
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2015-07-07
- Primary completion
- 2018-11-14
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.